设为首页 加入收藏

TOP

MIOSTAT(carbachol intraocular solution, USP)
2016-08-02 07:28:05 来源: 作者: 【 】 浏览:411次 评论:0
  • DESCRIPTION

    MIOSTAT® (carbachol intraocular solution, USP) is a sterile balanced salt solution of carbachol for intraocular injection. The active ingredient is represented by the chemical structure:

    
chemical

    Established name:

    Carbachol

    Chemical name:

    Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,Ntrimethyl-, chloride.

    Molecular Formula: C6H15CIN2O2

    Molecular Weight: 182.65

    Each mL contains: Active: carbachol 0.01%.

    Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dehydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and Water for Injection. pH range is 6.5-7.5.

  • CLINICAL PHARMACOLOGY

    Carbachol is a potent cholinergic (parasympathomimetic) agent which produces constriction of the iris and ciliary body resulting in reduction in intraocular pressure. The exact mechanism by which carbachol lowers intraocular pressure is not precisely known.

  • INDICATIONS AND USAGE

    Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery.

  • CONTRAINDICATIONS

    Should not be used in those persons showing hypersensitivity to any of the components of this preparation.

  • WARNINGS

    For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease.

    The vial stopper contains natural rubber (latex) which may cause severe allergic reactions.

  • PRECAUTIONS

    Use only if the container is undamaged.

    Carcinogenesis

    Studies in animals to eva luate the carcinogenic potential have not been conducted.

    Pregnancy

    Category C. There are no adequate and well-controlled studies in pregnant women. MIOSTAT® (carbachol intraocular solution, USP) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Nursing Mothers

    It is not known if this medication is excreted in breast milk. Exercise caution when administering to a nursing woman.

  • Pediatric Use

    Safety and efficacy in pediatric patients have not been established.

  • Geriatric Use

    No overall differences in safety or effectiveness have been observed between elderly and younger patients.

  • ADVERSE REACTIONS

    Ocular: Corneal clouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported.

    Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in urinary bladder, and headache have been reported with topical or systemic application of carbachol.

    The following additional reactions have been identified during post-approval use of MIOSTAT (carbachol intraocular solution, USP) in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to MIOSTAT, or a combination of these factors, include: corneal edema, drug effect prolonged (miosis), eye inflammation, eye pain, intraocular pressure increased, ocular hyperemia, vision blurred, visual impairment, and vomiting.

  • DOSAGE AND ADMINISTRATION

    Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.

  • HOW SUPPLIED

    In a 2.0 mL glass vial with a 1.5 mL fill, grey butyl stopper and aluminum seal packaged twelve to a carton.

    NDC 0065-0023-15

    STORAGE: Store at 15° - 30°C (59° - 86°F).

    Distributed by:
    Alcon Laboratories, Inc.
    Fort Worth, Texas 76134 USA

    © 2002, 2003, 2016  Novartis

    Revised: February 2016

    9012849-0216

  • PRINCIPAL DISPLAY PANEL

    NDC 0065-0023-15

    MIOSTAT®
    (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%

    TWELVE 1.5 mL Sterile Glass Vials

    Alcon®
    Alcon Laboratories, Inc., Fort Worth, Texas 76134 USA

    USUAL DOSAGE: 0.5 mL

    STORAGE: Store at 15 - 30C (59 - 86F).

    Rx Only

    INGREDIENTS: A sterile balanced salt solution containing (per mL) Active: carbachol 0.01%. Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dihydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection.

    LOT:

    EXP.:

    390121-0513

    carton

    MIOSTAT®
    (carbachol intraocular solution, USP) 0.01%


    Alcon®

    © 2001-2005 Alcon, Inc.

    320121-0305

    LOT:  EXP.:

    
label

    LOT:                EXP:              305190-1104

    NDC 0065-0023-15

    MIOSTAT®
    (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%       1.5mL

    Rx Only. Sterile Unless Package Open orDamaged Read enclosed insert.  INGREDIENTS:Active:carbachol 0.01%. Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dihydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection. USUAL DOSAGE: 0.5mL STORAGE: Store at 15° - 30°C (59° - 86°F).

    ©2004 Alcon, Inc.               Alcon Labs., Inc. Fort Worth, TX. 76134

    backing paper

        

  • INGREDIENTS AND APPEARANCE
    MIOSTAT   carbachol solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0065-0023
    Route of Administration OPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    CARBACHOL (UNII: 8Y164V895Y) (Carbamoylcholine - UNII:54Z8M50D6Q) CARBACHOL 0.1 mg  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    POTASSIUM CHLORIDE (UNII: 660YQ98I10)  
    CALCIUM CHLORIDE (UNII: M4I0D6VV5M)  
    MAGNESIUM CHLORIDE (UNII: 02F3473H9O)  
    SODIUM ACETATE (UNII: 4550K0SC9B)  
    TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    WATER (UNII: 059QF0KO0R)  
     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0065-0023-15 12 in 1 CARTON    
    1   1.5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product    
     
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA016968 04/15/1974  
    Labeler - Alcon Laboratories, Inc. (008018525)
    Registrant - Alcon Laboratories, Inc. (008018525)
    Establishment
    Name Address ID/FEI Business Operations
    Alcon Research Ltd   007672236 manufacture(0065-0023) 
  • 以下是“全球医药”详细资料
    Tags: 责任编辑:admin
    】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
    分享到QQ空间
    分享到: 
    上一篇INCRELEX (mecasermin [rDNA orig.. 下一篇奥培米芬片|Osphena(Ospemifene T..

    相关栏目

    最新文章

    图片主题

    热门文章

    推荐文章

    相关文章

    广告位